Language
English
Publication Date
5-1-2023
Journal
Future Oncology
DOI
10.2217/fon-2022-1040
PMID
37170847
Abstract
Several anti-HER2 agents are approved for third-line treatment and beyond (after first-line and second-line); however, no specific treatment strategy is recommended for third-line and beyond. Although these agents improve disease outcomes, HER2-positive metastatic breast cancer remains incurable and there is an unmet need for effective therapies in the later line setting. This review focuses on the development of margetuximab-cmkb, a novel, Fc-engineered, anti-HER2 monoclonal antibody, and its role in the systemic treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Keywords
Adult, Humans, Female, Breast Neoplasms, Receptor, ErbB-2, Antibodies, Monoclonal, Antineoplastic Agents, Neoplasms, Second Primary, Trastuzumab, Fc engineering, FcγRIIIA genotype, clinical trial, human epidermal growth factor receptor 2, margetuximab, metastatic breast cancer, monoclonal antibody
Published Open-Access
yes
Recommended Citation
Gradishar, William J; O'Regan, Ruth; Rimawi, Mothaffar F; et al., "Margetuximab in HER2-Positive Metastatic Breast Cancer" (2023). Faculty and Staff Publications. 4637.
https://digitalcommons.library.tmc.edu/baylor_docs/4637